Biostatistical Estimation of Tau Threshold Hallmarks (BETTH) Algorithm for Human Tau PET Imaging Studies

[1]  D. Minhas,et al.  CenTauR: Toward a universal scale and masks for standardizing tau imaging studies , 2023, Alzheimer's & dementia.

[2]  W. M. van der Flier,et al.  Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline , 2022, Nature Medicine.

[3]  Keith A. Johnson,et al.  Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment. , 2022, JAMA neurology.

[4]  Fanny Orlhac,et al.  A Guide to ComBat Harmonization of Imaging Biomarkers in Multicenter Studies , 2021, The Journal of Nuclear Medicine.

[5]  S. Gauthier,et al.  Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages. , 2021, Brain : a journal of neurology.

[6]  C. Jack,et al.  Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation , 2021, NeuroImage.

[7]  D. Minhas,et al.  Direct Comparison of the Tau PET Tracers 18F-Flortaucipir and 18F-MK-6240 in Human Subjects , 2021, The Journal of Nuclear Medicine.

[8]  A. Drzezga,et al.  Indication of retrograde tau spreading along Braak stages and functional connectivity pathways , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  W. Jagust,et al.  Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  D. Minhas,et al.  What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies , 2020, The Journal of Nuclear Medicine.

[11]  Joanne S. Robertson,et al.  Association of β-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals , 2020, Neurology.

[12]  Val J Lowe,et al.  Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. , 2020, JAMA neurology.

[13]  Gerrit Hirschfeld,et al.  cutpointr: Improved Estimation and Validation of Optimal Cutpoints in R , 2020, J. Stat. Softw..

[14]  Lisa Delano-Wood,et al.  Is tau in the absence of amyloid on the Alzheimer’s continuum?: A study of discordant PET positivity , 2019, Brain communications.

[15]  C. Rowe,et al.  Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease , 2019, Alzheimer's Research & Therapy.

[16]  O. Hansson,et al.  Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948 , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  D. Minhas,et al.  [18F]FDG, [11C]PiB, and [18F]AV-1451 PET Imaging of Neurodegeneration in Two Subjects With a History of Repetitive Trauma and Cognitive Decline , 2019, Front. Neurol..

[18]  A. Nordberg,et al.  Tau PET imaging in neurodegenerative tauopathies—still a challenge , 2019, Molecular Psychiatry.

[19]  B. Miller,et al.  Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders , 2018, JAMA.

[20]  S. Gauthier,et al.  In vivo quantification of neurofibrillary tangles with [18F]MK-6240 , 2018, Alzheimer's Research & Therapy.

[21]  Shannon L. Risacher,et al.  Topographic staging of tau positron emission tomography images , 2018, Alzheimer's & dementia.

[22]  John C. Morris,et al.  AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure , 2017, NeuroImage.

[23]  William J. Jagust,et al.  Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease , 2017, NeuroImage.

[24]  J. Morris,et al.  The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement , 2017, Alzheimer's & Dementia.

[25]  David T. Jones,et al.  Defining imaging biomarker cut points for brain aging and Alzheimer's disease , 2017, Alzheimer's & Dementia.

[26]  Suzanne L Baker,et al.  Reference Tissue–Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging , 2017, The Journal of Nuclear Medicine.

[27]  Talakad G. Lohith,et al.  Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles , 2016, The Journal of Nuclear Medicine.

[28]  Keith A. Johnson,et al.  A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers , 2016, Neurology.

[29]  M. Mintun,et al.  Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease , 2016, The Journal of Nuclear Medicine.

[30]  Daniel R. Schonhaut,et al.  Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. , 2016, Brain : a journal of neurology.

[31]  Daniel R. Schonhaut,et al.  PET Imaging of Tau Deposition in the Aging Human Brain , 2016, Neuron.

[32]  Keith A. Johnson,et al.  Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue , 2015, Annals of neurology.

[33]  Lennart Thurfjell,et al.  The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data , 2015, Alzheimer's & Dementia.

[34]  Jurgen Fripp,et al.  Robust inverse-consistent affine CT-MR registration in MRI-assisted and MRI-alone prostate radiation therapy , 2015, Medical Image Anal..

[35]  Robert A. Koeppe,et al.  The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET , 2015, Alzheimer's & Dementia.

[36]  Janna H. Neltner,et al.  Primary age-related tauopathy (PART): a common pathology associated with human aging , 2014, Acta Neuropathologica.

[37]  W. Chien,et al.  Current approaches to treatments for schizophrenia spectrum disorders, part II: psychosocial interventions and patient-focused perspectives in psychiatric care , 2013, Neuropsychiatric disease and treatment.

[38]  Arno Klein,et al.  101 Labeled Brain Images and a Consistent Human Cortical Labeling Protocol , 2012, Front. Neurosci..

[39]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[40]  Jeffrey A. James,et al.  Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.

[41]  A. Delacourte,et al.  The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease , 1999, Neurology.

[42]  Colin Studholme,et al.  Normalized entropy measure for multimodality image alignment , 1998, Medical Imaging.

[43]  H. Braak,et al.  Staging of alzheimer's disease-related neurofibrillary changes , 1995, Neurobiology of Aging.

[44]  Fionn Murtagh,et al.  Algorithms for hierarchical clustering: an overview , 2012, WIREs Data Mining Knowl. Discov..

[45]  Nikos Makris,et al.  Automatically parcellating the human cerebral cortex. , 2004, Cerebral cortex.